The Fed is getting smarter, cars are getting smarter, and we're getting smarter (and richer!) right along with them. Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
The Fed is getting smarter, cars are getting smarter, and we're getting smarter (and richer!) right along with them. Read More
Special Situations Portfolio Update – Argos TherapeuticsFor those of you participating in our current cancer treatment play (“One Little Shot to Kill Cancer Dead“), tomorrow is an important day. One of the three stocks we recommend in that bundle – Argos Therapeutics (ARGS) – is releasing its fourth quarter… Read More
Special Situations Portfolio Update – Argos TherapeuticsFor those of you participating in our current cancer treatment play (“One Little Shot to Kill Cancer Dead“), tomorrow is an important day. One of the three stocks we recommend in that bundle – Argos Therapeutics (ARGS) – is releasing its fourth quarter… Read More
After trying privately to convince Yahoo’s board of directors to pursue a new strategic direction for more than a year, this week hedge fund investor Starboard Value went public with its plan to oust the entire board and replace it with one of its choosing. Read More
- March 21, 2016
-
Download Issue
As we pivot into the next major long term economic cycle, the stock market is searching for a new set of companies to lead it higher and we believe it is companies such as these that will do it. Read More
As we pivot into the next major long term economic cycle, the stock market is searching for a new set of companies to lead it higher and we believe it is companies such as these that will do it. Read More
Long time subscribers to Smart Tech Investor may recall our story from last June on exoskeleton technology (“From Comic Books to Reality: Exoskeletons Are Here to Stay“), which recommended three companies that are currently held in our Special Situations Portfolio: Ekso Bionics (EKSO), ReWalk Robotics (RWLK) and Parker Hannifin (PH). Read More
Long time subscribers to Smart Tech Investor may recall our story from last June on exoskeleton technology (“From Comic Books to Reality: Exoskeletons Are Here to Stay“), which recommended three companies that are currently held in our Special Situations Portfolio: Ekso Bionics (EKSO), ReWalk Robotics (RWLK) and Parker Hannifin (PH). Read More
All three of our Special Situations Portfolio "cancer stocks" - companies that are on the cutting edge of developing revolutionary treatment for some of the worst forms of cancer, were in the news recently. And almost all of the news was good, with all three stocks moving up smartly as a result. Read More